| abstract |
Agent (A) for treating human disease is based on substances (I) that modulate (inhibit or promote) the interaction of beta -catenin (bC) with transcription factors or products of tumor suppressor genes. Independent claims are also included for the following: (a) peptide (II) comprising part of the LEF-1/TCF-4 transcription factors, or their variants and mutants; (b) peptide and related molecules (III) from the armadillo domain (arm units 3-8) of bC, and mutants of the complete bC molecule, that include at least one of the specific interaction domains for LEF-1, TCF-4, APC, conductin or E-cadherin; and (c) enzyme-linked immunosorbent assay (ELISA) for screening substance libraries for compounds that modulate interaction of bC with LEF-1/TCF, APC, conductin or E-cadherin. |